Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04022980 · ClinicalTrials.gov registry record · Phase 1
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04022980 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants.
The verdict
NCT04022980, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a tolerated dose (based on dose-limiting toxicities) for the expansion phase of the study (Stage 2).The primary objective of Stage 2 is to evaluate the efficacy of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in terms of the 2-year progression-free survival rate and compare to relevant historical controls
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-03-31 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04022980
The ClinicalTrials.gov registry entry for NCT04022980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT04022980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04022980 about?
NCT04022980 is a clinical study titled "Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma". The primary objective of Stage 1 is to evaluate the safety of nivolumab consolidation after completion of HD-MTX containing induction chemotherapy in older subjects with PCNSL in terms of a tolerated dose (based on dose-limiting toxicities) for the expansion phase of the study (Stage 2).The primary ...
What is the current status of trial NCT04022980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-03-31. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT04022980?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT04022980?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.